{"id":"immunomodulatory-treatment-by-rituximab","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Infusion reactions"},{"rate":"10-20%","effect":"Infections"},{"rate":"5-10%","effect":"Neutropenia"},{"rate":"5-10%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL1201576","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This results in a reduction in B cell count and function, which can help to alleviate symptoms and slow disease progression in conditions such as rheumatoid arthritis and non-Hodgkin lymphoma. Rituximab's mechanism of action is primarily through the depletion of B cells, but it may also have effects on other immune cells and cytokines.","oneSentence":"Rituximab works by binding to the CD20 antigen on the surface of B cells, leading to their depletion and subsequent immunomodulation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:15:42.931Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-Hodgkin lymphoma"},{"name":"Rheumatoid arthritis"}]},"trialDetails":[{"nctId":"NCT05931718","phase":"","title":"Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia","status":"RECRUITING","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2019-06-01","conditions":"Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, Chronic Idiopathic Neutropenia","enrollment":200},{"nctId":"NCT05848765","phase":"PHASE2","title":"Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2023-09-04","conditions":"Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma","enrollment":284},{"nctId":"NCT05946486","phase":"PHASE3","title":"Evaluation of the Efficacy of Immunomodulatory Therapy in Case of Psychiatric Disorders With Proven Dysimmunity.","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2023-10-15","conditions":"Mental Disorder","enrollment":174},{"nctId":"NCT05415579","phase":"","title":"Demyelinating Diseases of the Central Nervous System Registry for Patients With Traditional Chinese Medicine (DATE-TCM)","status":"NOT_YET_RECRUITING","sponsor":"Dongzhimen Hospital, Beijing","startDate":"2022-06-20","conditions":"Demyelinating Diseases of the Central Nervous System (DDC)","enrollment":2000},{"nctId":"NCT01088048","phase":"PHASE1","title":"Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-03-25","conditions":"Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma","enrollment":241},{"nctId":"NCT01451879","phase":"","title":"Observational Study for Subjects With Pompe Disease Undergoing Immune Modulation Therapies","status":"COMPLETED","sponsor":"University of Florida","startDate":"2008-10","conditions":"Pompe Disease","enrollment":11},{"nctId":"NCT00230035","phase":"PHASE2","title":"Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-09","conditions":"Systemic Lupus Erythematosus","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"immunomodulatory treatment by rituximab","genericName":"immunomodulatory treatment by rituximab","companyName":"University Hospital, Bordeaux","companyId":"university-hospital-bordeaux","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rituximab works by binding to the CD20 antigen on the surface of B cells, leading to their depletion and subsequent immunomodulation. Used for Non-Hodgkin lymphoma, Rheumatoid arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}